Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa

项目 2：马拉维和南非当地标准护理治疗下 HIV 相关卡波西肉瘤进展的临床和分子决定因素

• 批准号: 10238161
• 负责人: Dirk P Dittmer
• 金额: $ 18.45万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-13 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10238161
• 关键词: AIDS Malignancy Consortium; AIDS clinical trial group; AIDS related cancer; AIDS with Kaposi' s sarcoma; Adopted; Africa; Africa South of the Sahara; Area; Biological; Biopsy; Bleomycin; Blood; Caring; Cells; Clinical; Clinical Markers; Clinical Trials; Cohort Studies; Collaborations; Collection; Country; Data Set; Detection; Disease; Disease Marker; Doxorubicin Hydrochloride Liposome; Eligibility Determination; Enrollment; Europe; Funding; Gene Expression Profile; Gene Expression Profiling; Genetic Transcription; Genome; Genomics; Goals; HIV; Hospitals; Human; Human Herpesvirus 8; IL6 gene; Incidence; Institutional Review Boards; Interleukin-10; Iris; Joints; Kaposi Sarcoma; Link; Liposomal Doxorubicin; Lymphoma; Lymphoproliferative Disorders; Malawi; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Malignant neoplasm of prostate; Mentors; Molecular; North Carolina; Nucleotides; Paclitaxel; Pathogenesis; Pathology; Patients; Population; Positioning Attribute; Prognosis; Prognostic Factor; Prognostic Marker; Public Sector; Publications; Randomized Clinical Trials; Research; Research Personnel; Saliva; Shipping; Site; South Africa; Stains; Testing; Time; Trust; United States National Institutes of Health; Universities; Variant; Vincristine; Viral; Viral Load result; Work; base; biomarker performance; cohort; exceptional responders; exosome; experience; genome sequencing; innovation; low and middle-income countries; men; molecular marker; outcome prediction; response; response biomarker; screening; sex; standard of care; treatment guidelines; treatment response; whole genome

ABSTRACT: PROJECT 2. Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa This application seeks to establish the UNC-Malawi-South Africa Cancer Consortium (UMSACC). It responds to RFA-CA-20-001 and will establish a research center to develop capacity and conduct high-impact research focused on HIV-Associated Malignancy in U.S. and Low- and Middle-Income Country. Project 2 - Kaposi Sarcoma builds on longstanding collaborations between the University of North Carolina at Chapel Hill, Lighthouse Trust / Kamuzu Central Hospital in Malawi, and Stellenbosch University / Tygerberg Hospital in South Africa. This project has participation of investigators from all three countries: the US, Malawi and South Africa. UMSACC will establish and maintain core that support mentoring, administration, pathology and analyses jointly across three projects. Kaposi sarcoma is by far the most common cancer in people living in with HIV in Sub Saharan Africa and the US standard of care, liposomal doxorubicin, is not affordable or available in the public sector. Building on recent randomized clinical trials by the AIDS malignancy Consortium and the AIDS clinical trials group, we will document the experience with paclitaxel/ cART as new first line therapy in HIV-KS and seek to develop prognostic biomarkers of the disease, such as KSHV viral load, IL6, KSHV sequence variants and KSHV transcription.

摘要：项目2。HIV相关Kaposi肉瘤的临床和分子决定因素 马拉维和南非当地标准治疗的进展 本申请旨在建立联合国大学-马拉维-南非癌症联合会。它响应 RFA-CA-20-001，并将建立一个研究中心，以发展能力和进行高影响力的研究 专注于 美国和中低收入国家的艾滋病相关疾病。项目2 -卡波西 肉瘤建立在查佩尔山的北卡罗来纳州大学， 马拉维灯塔信托基金/卡穆祖中心医院和马拉维斯泰伦博斯大学/泰格伯格医院。 南非该项目有来自所有三个国家的调查人员参与：美国，马拉维和南苏丹。 非洲USSACC将建立和维护支持指导，管理，病理学和 对三个项目进行联合分析。卡波西肉瘤是迄今为止最常见的癌症， 在撒哈拉以南非洲和美国的标准治疗中，脂质体阿霉素是负担不起的， 在公共部门可用。基于艾滋病恶性肿瘤协会最近的随机临床试验 和艾滋病临床试验组，我们将记录紫杉醇/ cART作为新一线治疗的经验 HIV-KS的治疗，并寻求开发疾病的预后生物标志物，如KSHV病毒载量，IL 6， KSHV序列变体和KSHV转录。